- Home
- MP vs EXEL Comparison
MP vs EXEL Comparison
Compare MP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- EXEL
- Stock Information
- Founded
- MP 2017
- EXEL 1994
- Country
- MP United States
- EXEL United States
- Employees
- MP N/A
- EXEL 1147
- Industry
- MP Metal Mining
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MP Basic Materials
- EXEL Health Care
- Exchange
- MP Nasdaq
- EXEL Nasdaq
- Market Cap
- MP 12.9B
- EXEL 10.4B
- IPO Year
- MP N/A
- EXEL 2000
- Fundamental
- Price
- MP $75.05
- EXEL $38.31
- Analyst Decision
- MP Buy
- EXEL Buy
- Analyst Count
- MP 8
- EXEL 21
- Target Price
- MP $54.75
- EXEL $43.65
- AVG Volume (30 Days)
- MP 13.8M
- EXEL 4.0M
- Earning Date
- MP 08-07-2025
- EXEL 07-28-2025
- Dividend Yield
- MP N/A
- EXEL N/A
- EPS Growth
- MP N/A
- EXEL 81.76
- EPS
- MP N/A
- EXEL 2.08
- Revenue
- MP $242,116,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- MP $40.55
- EXEL $9.88
- Revenue Next Year
- MP $121.77
- EXEL $12.59
- P/E Ratio
- MP N/A
- EXEL $18.45
- Revenue Growth
- MP 39.42
- EXEL 10.73
- 52 Week Low
- MP $11.87
- EXEL $25.12
- 52 Week High
- MP $82.50
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- MP 74.57
- EXEL 41.08
- Support Level
- MP $72.14
- EXEL $37.01
- Resistance Level
- MP $78.16
- EXEL $38.78
- Average True Range (ATR)
- MP 4.77
- EXEL 1.12
- MACD
- MP -0.02
- EXEL 0.07
- Stochastic Oscillator
- MP 68.03
- EXEL 83.79
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.